Home › Chronic Inflammatory Demyelinating Polyradiculoneuropathy › Wisconsin › Milwaukee
Chronic Inflammatory Demyelinating Polyradiculoneuropathy clinical trials in Milwaukee, WI
4 studies for Chronic Inflammatory Demyelinating Polyradiculoneuropathy are looking for participants at sites in and around Milwaukee (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RecruitingPhase 2
- Site Number - 1613, Milwaukee
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RecruitingPhase 2/3
- Advocate Health - Aurora St. Luke's Medical Center, Milwaukee
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
RecruitingPhase 1
- TG Therapeutics Investigational Trial Site, Milwaukee
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
RecruitingPhase 3
- BCN Research, LLC, Greenfield · 8 mi away
Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials in other cities
- New York City, NY7 studies
- Miami, FL6 studies
- Houston, TX6 studies
- Kansas City, KS5 studies
- Indio, CA5 studies
- Philadelphia, PA5 studies
- St. Louis, MO5 studies
- New Haven, CT5 studies
- Tampa, FL4 studies
- Cleveland, OH4 studies
- Washington, DC4 studies
- Birmingham, AL4 studies
Other studies in Milwaukee
- Breast Cancer23 studies
- Non-Small Cell Lung Cancer22 studies
- Cancer (all types)22 studies
- Lung Cancer21 studies
- Multiple Myeloma21 studies
- Prostate Cancer20 studies
- Follicular Lymphoma19 studies
- Pancreatic Cancer18 studies
- Non-Hodgkin Lymphoma18 studies
- Ovarian Cancer17 studies
- Acute Myeloid Leukemia17 studies
- Burkitt Lymphoma16 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.